Dr. Kipp Weiskopf is a Valhalla Fellow at the Whitehead Institute. Dr. Weiskopf’s lab studies novel macrophage and myeloid immune checkpoints. Weiskopf began studying the CD47/SIRP⍺ interaction as a graduate student and demonstrated that CD47-blocking therapies could unleash immune attack against cancer and enhance a number of existing therapies. He also showed they could be used to treat small cell lung cancer and might permit bone marrow transplantation without using chemotherapy or radiation. The Weiskopf lab studies additional mechanisms that control myeloid cell activation in tumors to develop new treatments for cancer and other life-threatening diseases, such as COVID-19.